ERBB2 and breast cancer: A total of seven CD274/PD-L1 CN gains (0.4%, 7/1918) and five PD-L1 CN deletions (0.3%, 5/1918) were identified, and only one sample originated from primary breast cancer with the HER2 subtype and the other samples were from metastatic sites.